A Comparison of Intravitreal Bevacizumab and Steroid Activity in an Experimental Uveitis Model

REFERENCES

• Smith RL, Baarsma GS, de Vries J. Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital. Int Ophthalmol 1993;17:71–75
   PubMed Web of Science ®Google Scholar
• Forrester JV. Autoimmunity and autoimmune disease of the eye. Dev Ophthalmol 1999;30:167–186
   PubMedGoogle Scholar
• Rosenbaum JT, Samples JR, Hefeneider SH. Ocular inflammatory effects of intravitreal interleukin-1. Arch Ophthalmol 1987;105:1117–1120
   PubMed Web of Science ®Google Scholar
• Vinores SA, Chan CC, Vinores MA, Matteson DM, Chen YS, Klein DA, et al. Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol 1998;89:43–50
   PubMed Web of Science ®Google Scholar
• Paroli MP, Teodori C, D'Alessandro M, Mariani P, Iannucci G, Paroli M. Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis. Eur J Ophthalmol 2007;17:938–942
   PubMed Web of Science ®Google Scholar
• Bates D, Hillman N, Pocock T, Neal C. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002;200:529–530
   Web of Science ®Google Scholar
• Cekmen M, Evereklioglu C, Er H, Inalöz HS, Doganay S, Türköz Y, Ozerol IH. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome. Int J Dermatol. 2003;42:870–875
   PubMed Web of Science ®Google Scholar
• Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001;132:794–796
   PubMed Web of Science ®Google Scholar
• Özkırış A, Erkılıç K, İlhan Ö, Tuzcu E. Evaluation of the efficacy of intravitreal injection of triamcinolone acetonide in patients with pseudophakic cystoid macular edema. Erciyes Med J 2007;29:290–293
   Google Scholar
• Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249–258
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, et al. Acute endophthalmitis following intravitreal triamcinolone acetonoid injection. Am J Ophthalmol 2003;136:790–796
   Google Scholar
• Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection of triamcinolone. Arch Ophthalmol 2004;122:336–340
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328–335
   PubMed Web of Science ®Google Scholar
• Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:1574–1579.e1
   PubMed Web of Science ®Google Scholar
• Tilton RG, Chang K, Corbett JA, Misko TP, Currie MG, Bora NS, et al. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci 1994;35:3278–3288
   PubMed Web of Science ®Google Scholar
• Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303–324
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor, vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995;146:1029–1039
   PubMed Web of Science ®Google Scholar
• Luna JD, Chan CC, Derevjanik NL, Mahlow J, Chiu C, Peng B, et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res 1997;49:268–280
   PubMed Web of Science ®Google Scholar
• Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820–1828
   PubMed Web of Science ®Google Scholar
• McMenamin PG, Forrester JV, Steptoe R, Dua HS. Ultrastructural pathology of experimental autoimmune uveitis in the rat. Autoimmunity 1993;16:83–93
   PubMed Web of Science ®Google Scholar
• Greenwood J. The blood-retinal barrier in experimental autoimmune uveoretinitis (EAU): a review. Curr Eye Res 1992;11:25–32
   PubMed Web of Science ®Google Scholar
• Vinores SA, Youssri AI, Luna JD, Chen YS, Bhargave S, Vinores MA, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997;12:99–109
   PubMed Web of Science ®Google Scholar
• Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:574–584
   PubMed Web of Science ®Google Scholar
• de Kozak Y, Sakai J, Thillaye B, Faure JP. S antigen-induced experimental autoimmune uveo-retinitis in rats. Curr Eye Res 1981;1:327–337
   PubMed Web of Science ®Google Scholar
• Ramanathan S, de Kozak Y, Saoudi A, Goureau O, Van der Meide PH, Druet P, et al. Recombinant IL-4 aggravates experimental autoimmune uveoretinitis in rats. J Immunol 1996;157:2209–2215
   PubMed Web of Science ®Google Scholar
• Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma 2002;11:406–410
   PubMed Web of Science ®Google Scholar
• Webb NJ, BottomLey MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implication for measurement of circulating VEGF concentrations in clinical disease. Clin Sci 1998;94:395–404
   PubMed Web of Science ®Google Scholar
• Nielson HJ, Werther K, Mynster T, Brünner N. Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion 1999;39:1078–1083
   PubMed Web of Science ®Google Scholar
• Qian CN, Zhang CQ, Guo X, Hong MH, Cao SM, Mai WY, et al. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer Res 2000;88:255–261
   Google Scholar
• Davies MM, Jonas SK, Kaur S, Allen-Mersh TG. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume. Br J Cancer 2000;82:1004–1008
   PubMed Web of Science ®Google Scholar
• Duque JLF, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523–527
   PubMed Web of Science ®Google Scholar
• Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997;64:505–517
   PubMed Web of Science ®Google Scholar
• Alikacem N, Yoshizawa T, Nelson KD, Wilson CA. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits. Invest Ophthalmol Vis Sci 2000;41:1561–1569
   PubMed Web of Science ®Google Scholar
• Wong CG, Rich KA, Liaw LH, Hsu HT, Berns MW. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr Eye Res 2001;22:140–147
   PubMed Web of Science ®Google Scholar
• Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol 1999;97:297–309
   PubMed Web of Science ®Google Scholar
• Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 2002;10:239–246
   PubMed Web of Science ®Google Scholar
• Severinghaus JW. Hypothetical roles of angiogenesis, osmotic swelling, and ischemia in high-altitude cerebral edema. J Appl Physiol 1995;79:375–379
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920–927
   PubMed Web of Science ®Google Scholar
• Hernaez-Ortega M, Soto-Pedre, E. A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging 2004;35:350–351
   PubMed Web of Science ®Google Scholar
• Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1–9
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336–339
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005;89:1368–1370
   PubMed Web of Science ®Google Scholar
• Ziemssen F, Deuter CM, Stuebiger N, Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefe's Arch Clin Exp Ophthalmol 2007;245:917–918
   PubMed Web of Science ®Google Scholar